Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $202.29 Consensus Target Price from Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has been given a consensus rating of “Buy” by the eight analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $202.29.

Several analysts recently commented on KRYS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Evercore ISI lifted their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Citigroup lifted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Tuesday, November 5th.

Krystal Biotech Price Performance

KRYS stock opened at $184.40 on Friday. Krystal Biotech has a 1-year low of $103.83 and a 1-year high of $219.34. The business has a fifty day moving average price of $181.31 and a 200-day moving average price of $184.78. The stock has a market capitalization of $5.30 billion, a P/E ratio of 104.18 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. During the same quarter in the previous year, the business earned ($0.67) earnings per share. The company’s revenue was up 879.9% on a year-over-year basis. As a group, analysts anticipate that Krystal Biotech will post 2.97 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 14.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds have recently made changes to their positions in the business. State Street Corp boosted its stake in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after acquiring an additional 119,936 shares during the period. Geode Capital Management LLC boosted its stake in shares of Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after acquiring an additional 11,411 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Krystal Biotech by 1.3% in the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock worth $106,593,000 after acquiring an additional 7,537 shares during the period. Hood River Capital Management LLC boosted its stake in shares of Krystal Biotech by 5.1% in the second quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock worth $95,694,000 after acquiring an additional 25,507 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after acquiring an additional 62,178 shares during the period. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).